Competition in the med-tech space is fierce, and rival executives and
sales reps live to take away accounts and revenue from other companies.
In markets like cardiac rhythm management, cardiology, and
neuromodulation, Medtronic (NYSE: MDT ) is a fierce competitor to Boston Scientific (NYSE: BSX ) and St. Jude Medical (NYSE: STJ )
, with the latter two often getting the worse of the head-to-head
battles. Now there is word that Medtronic has once again thrown a
spanner into St. Jude's works, and this time, it wasn't even deliberate.
Word has come out that St. Jude is going back to the drawing board
with its pivotal trial for the EnligHTN IV renal denervation device -- a
product that St. Jude clearly hopes will be a winner in a battle for a
market that could ultimately be measured in the billions of dollars.
While this delay is not likely to be fatal to the future of St. Jude's
ambitions in renal denervation, it does underline how inadvertent
competition can still take a toll.
Please read more here:
http://www.fool.com/investing/general/2013/12/12/medtronic-unnerves-a-major-rival.aspx
No comments:
Post a Comment